Literature DB >> 26314697

Prevalence of Renal Impairment in Patients With Rheumatoid Arthritis: Results From a Cross-Sectional Multicenter Study.

Marion Couderc1, Zuzana Tatar1, Bruno Pereira1, Aurélien Tiple1, Mélanie Gilson2, Bruno Fautrel3, Sophie Pouplin4, Emmanuelle Dernis5, Laure Gossec6, Cécile Gaujoux-Viala7, Martin Soubrier1, Maxime Dougados8.   

Abstract

OBJECTIVE: To assess the prevalence and associations of renal dysfunction in patients with rheumatoid arthritis (RA).
METHODS: COMEDRA is a French nationwide cross-sectional multicenter study on comorbidities in RA. Renal function was assessed from the estimated glomerular filtration rate (eGFR), using the Modification of Diet in Renal Disease equation. RA characteristics and risk factors for renal impairment were collected. Two logistic regression models, 1 with and 1 without the Framingham Risk Score, were constructed from variables that were significantly associated with an eGFR of <60 ml/minute/1.73 m(2) or were clinically relevant.
RESULTS: Of the 970 recruited patients, 931 were analyzed (women 79.6%, mean age 57.8 years, disease duration 11.1 years, Disease Activity Score in 28 joints using the erythrocyte sedimentation rate [DAS28-ESR] 3.1). A total of 82 patients (8.8%) had an eGFR <60 ml/minute/1.73 m(2) and 9% had proteinuria. In univariate analysis, renal impairment was associated with age (P < 0.001), history of hypertension (P < 0.001), high systolic blood pressure (P = 0.03), and the Systematic Coronary Risk Evaluation (SCORE) equation (P = 0.002), but not with sex, disease duration, disease activity (as assessed by DAS28-ESR), nonsteroidal antiinflammatory drug use, disease severity (erosions, joint replacement), or RA medications. Multivariate analysis models showed that age (odds ratio [OR] 1.05 [95% confidence interval (95% CI) 1.03-1.09]) and hypertension (OR 2.5 [95% CI 1.5-4.3]) were associated with renal impairment. A second model showed that the SCORE equation (OR 1.33 [95% CI 1.06-1.67]) was associated with renal impairment.
CONCLUSION: Renal impairment is relatively common in RA and is associated with cardiovascular risk factors such as age, hypertension, and the SCORE equation but not with disease activity or severity.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Year:  2016        PMID: 26314697     DOI: 10.1002/acr.22713

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  6 in total

1.  Renal dysfunction among rheumatoid arthritis patients: A retrospective cohort study.

Authors:  Ashraf O Oweis; Khaldoon M Alawneh; Sameeha A Alshelleh; Fatima Alnaimat; Diala Alawneh; Deeb Jamil Zahran
Journal:  Ann Med Surg (Lond)       Date:  2020-11-04

2.  Prediction of Renal Function Damage in Patients with Essential Hypertension Based on Stepwise Regression Equation Scanning by AASI.

Authors:  Yaqiong Wu; Guangyu Ma; Hongzhen Sun; Sijie Zhang; Xingtao Li
Journal:  Scanning       Date:  2022-05-28       Impact factor: 1.750

3.  Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction.

Authors:  Jung Sun Lee; Ji Seon Oh; Yong-Gil Kim; Chang-Keun Lee; Bin Yoo; Seokchan Hong
Journal:  Rheumatol Int       Date:  2020-03-13       Impact factor: 2.631

Review 4.  Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs.

Authors:  William F C Rigby; Kathy Lampl; Jason M Low; Daniel E Furst
Journal:  Int J Rheumatol       Date:  2017-10-31

5.  Prevalence of and factors associated with renal dysfunction in rheumatoid arthritis patients: a cross-sectional study in community hospitals.

Authors:  Shunsuke Mori; Tamami Yoshitama; Naoyuki Hirakata; Yukitaka Ueki
Journal:  Clin Rheumatol       Date:  2017-09-07       Impact factor: 2.980

6.  Impaired renal functions in Pakistani cohort of rheumatoid arthritis.

Authors:  Abrar Ahmed Wagan; Sadia Nasir; Abdul Rahim; Daim Khan
Journal:  Pak J Med Sci       Date:  2019 Jul-Aug       Impact factor: 1.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.